Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 16 April 2025Expected publication date: 21 May 2025
Pembrolizumab with carboplatin and paclitaxel for untreated advanced or recurrent endometrial cancer [ID6381]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 14 April 2025Expected publication date: TBC